Clinical Trial

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II single center study to administer two courses of myeloablative consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC) rescue in patients with high-risk neuroblastoma who have completed induction chemotherapy (independent of this study). Ideally, patients should begin consolidation chemotherapy no later than 8 weeks after the start of Induction Cycle #5; however it is strongly recommended to begin consolidation within 4-6 weeks after the start of Induction Cycle #5.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2015-11-12; most recent amendment 2025-10-20.
Status change: Not Yet Recruiting → Recruiting 2016-06-07
Trial Details
NCT Number NCT02605421
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Neuroblastoma
Enrollment 12 participants
Start Date 2016-06
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-21